Answers are grounded in this paper and cite their sources.
Decitabine-cedazuridine is an oral fixed-dose combination developed to achieve systemic decitabine exposure comparable to intravenous (IV) decitabine through inhibition of cytidine deaminase by cedazuridine. In combination with venetoclax, it enables a fully oral hypomethylating agent (HMA)-venetoclax regimen for older adults and patients with acute myeloid leukemia (AML) who are unsuitable for intensive chemotherapy. Pharmacokinetic bridging studies demonstrated exposure equivalence between oral decitabine-cedazuridine and IV decitabine, while subsequent prospective studies established the feasibility, safety, and clinical activity of the oral combination with venetoclax. The principal advantage of this approach is reduced reliance on parenteral HMA administration rather than demonstrated superiority in antileukemic efficacy or tolerability compared with established HMA-venetoclax regimens. Myelosuppression and infectious complications remain the dominant toxicities and frequently necessitate response-adapted treatment modifications, treatment delays, growth-factor support, and ongoing monitoring. Emerging data are now extending the use of decitabine-cedazuridine as an oral backbone for post-transplant maintenance strategies and molecularly targeted combination regimens incorporating targeted agents, including menin and FLT3 inhibitors. This review summarizes the pharmacology, pharmacokinetics, clinical efficacy, safety, practical administration, and evolving role of decitabine-cedazuridine in AML, while highlighting current evidence gaps and priorities for future research.
No takes yet. Share an insight, caveat, or question.
Htut et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: